Other News To Note
Daiichi Sankyo Co. Ltd., of Tokyo, reported results of a prespecified subgroup analysis of 771 cancer patients enrolled in the Phase III Hokusai-VTE study, showing that subjects with either a history of cancer or with active cancer treated with once-daily Factor Xa inhibitor edoxaban had a numerically lower incidence of recurrent symptomatic venous thromboembolism compared to warfarin (3.7 percent vs. 7.1 percent).
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter